ABI
ALXN

Adamant Biomedical Investments’s Alexion Pharmaceuticals ALXN Stock Holding History

Adamant Biomedical Investments’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		$10.5M Sell
57,000
-3,000
-5% -$556K 2.52% 9
2014
Q3 		$9.95M Buy
+60,000
New +$9.85M 2.48% 10

Other funds holding ALXN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Adamant Biomedical Investments's ALXN Position: Q4 2014 in Review

Adamant Biomedical Investments reduced its Alexion Pharmaceuticals (ALXN) stake by 5% in Q4 2014, selling an estimated $556K and leaving 57,000 shares worth $10.5M. The position accounts for 2.52% of the portfolio, ranked #9.

Adamant Biomedical Investments first reported a position in ALXN in Q3 2014 and has held it in 2 quarters since. 579 funds tracked by Wall St. Rank hold ALXN as of Q4 2014.

  • Adamant Biomedical Investments held 57,000 shares of Alexion Pharmaceuticals worth $10.5M as of Q4 2014.
  • Adamant Biomedical Investments sold 3,000 Alexion Pharmaceuticals shares in Q4 2014, an estimated $556K.
  • Alexion Pharmaceuticals made up 2.52% of Adamant Biomedical Investments's portfolio in Q4 2014, its #9 holding.
  • Adamant Biomedical Investments first reported a position in Alexion Pharmaceuticals in Q3 2014 and has held it in 2 quarters since.
  • 579 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2014.

Based on Adamant Biomedical Investments's 13F filing for Q4 2014, filed 13 Feb 2015.